Eazy Testing Inc. Becomes AditxtScore™ Channel Partner, to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring wit...
March 04 2021 - 8:30AM
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the
“Company”) (Nasdaq: ADTX), a biotech innovation company focused on
improving the health of the immune system, today announced that
Eazy Testing Inc. will be offering AditxtScore™ for COVID-19
throughout its California locations.
Eazy Testing offers walk-in and concierge
COVID-19 testing services, including several rapid tests, at its
nine current locations throughout California. Eazy Testing also
provides at-location services for individuals and groups and
pre-tests passengers for approval to fly.
As an AditxtScore™ Channel Partner, Eazy Testing
will now offer its clients, including consumers and employers,
AditxtScore™ for COVID-19 as an immune monitoring service. This
service will complement Eazy Testing’s current offerings and
provide key information regarding immunity status to its customers.
Specimens collected by Eazy Testing will be processed by Aditxt’s
CLIA accredited AditxtScore™ Center.
Dr. Albert Elhiani, D.P.M., co-founder and CEO
of Eazy Testing, said, “Knowing your immunity status will be
crucial for broadly opening the economy and is expected to drive
demand for AditxtScore™ for COVID-19. Aditxt’s unique monitoring
service provides comprehensive information on an individual’s
protective immunity and is a great addition to our product
roster.”
Amro Albanna, co-founder and CEO of Aditxt,
added, “As we move through this next phase of the pandemic,
immunity status will be key to returning to normalcy. We believe
that offering individuals a more complete view of their immune
system provides the best chance for them to make informed personal
health and safety decisions. We look forward to working with the
Eazy Testing team and expanding our AditxtScore™ Channel Partner
network of labs and hospitals around the country and
worldwide.”
For more information on AditxtScore and how it can bolster your
COVID-19 testing efforts, visit aditxtscore.com
About Aditx Therapeutics
Aditxt is developing technologies specifically
focused on improving the health of the immune system through immune
monitoring and reprogramming. The immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. The immune reprogramming technology is currently at
the pre-clinical stage and is designed to retrain the immune system
to induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements” within the meaning of the
federal securities laws. Forward looking statements include
statements regarding the Company’s intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company’s ongoing and planned product
development; the Company’s intellectual property position; the
Company’s ability to develop commercial functions; expectations
regarding product launch and revenue; the Company’s results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section entitled “Risk Factors” in the Company’s
prospectus, dated February 10, 2021, that was filed with the
Securities and Exchange Commission under File No. 333-252711, as
well as discussions of potential risks, uncertainties, and other
important factors in the Company’s subsequent filings with the
Securities and Exchange Commission. All such statements speak only
as of the date made, and the Company undertakes no obligation to
update or revise publicly any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations:
PCG Advisory Jeff RamsonChief Executive OfficerIR@aditxt.com
646-863-6341
Public RelationsKevin Harrington5W Public
Relationsaditxt@5wpr.com
www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Sep 2023 to Sep 2024